Show simple item record

dc.contributor.authorVerma, V.*
dc.contributor.authorRyckman, J.M.*
dc.contributor.authorSimone, C.B.*
dc.date.accessioned2019-05-17T12:53:05Z
dc.date.available2019-05-17T12:53:05Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85025175780&doi=10.1080%2f0284186X.2017.1351039&partnerID=40&md5=13ffbdd58ddb9c0c44fd97658d6c454a
dc.identifier.urihttp://hdl.handle.net/10713/9097
dc.description.abstractPurpose: The standard of care for stage I (T1N0) nasopharyngeal cancer (NPC) is definitive radiotherapy (RT). Given the phase III evidence supporting combined chemoradiotherapy (CRT) for stage II NPC, we investigated practice patterns and outcomes associated with administration of chemotherapy to RT alone for stage I NPC. Methods: The National Cancer Data Base (NCDB) was queried for clinical T1N0 primary NPC cases (2004-2013) receiving curative-intent RT. Patients with unknown RT/chemotherapy status were excluded, as were benign/sarcomatous histologies and receipt of pharyngectomy. Patient, tumor, and treatment parameters were extracted. Logistic regression analysis ascertained factors associated with receipt of additional chemotherapy. Kaplan-Meier analysis was used to evaluate overall survival (OS) between patients receiving RT versus CRT. Cox proportional hazards modeling determined variables associated with receipt of OS. Results: In total, 396 patients were analyzed. Chemotherapy was delivered in 147 patients (37%). On multivariate analysis, patients treated at academic/integrated centers were less likely to receive chemotherapy (p =.008); a racial predilection was noted, as non-black/non-white patients were also less likely to receive chemotherapy (p =.006). Respective 5-year OS in patients receiving RT alone versus CRT were 77% and 75% (p =.428). Receipt of chemotherapy did not independently predict for greater OS (p =.447). Conclusions: These data do not support the routine addition of chemotherapy to definitive RT for T1N0 NPC. Copyright 2017 Acta Oncologica Foundation.en_US
dc.description.urihttps://dx.doi.org/10.1080/0284186X.2017.1351039en_US
dc.language.isoen_USen_US
dc.publisherTaylor and Francis Ltden_US
dc.relation.ispartofActa Oncologica
dc.subject.lcshNasopharynx--Canceren_US
dc.subject.meshChemoradiotherapyen_US
dc.titlePatterns of care and outcomes with the addition of chemotherapy to radiation therapy for stage I nasopharyngeal canceren_US
dc.typeArticleen_US
dc.identifier.doi10.1080/0284186X.2017.1351039
dc.identifier.pmid28723264


This item appears in the following Collection(s)

Show simple item record